<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01768260</url>
  </required_header>
  <id_info>
    <org_study_id>Eye EECP-1</org_study_id>
    <nct_id>NCT01768260</nct_id>
  </id_info>
  <brief_title>Effect of EECP on Anterior Ischemic Optic Neuropathy</brief_title>
  <acronym>AION</acronym>
  <official_title>Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function
      by improving  the blood perfusion of eyes. The present study aims to investigate the effect
      of EECP on Anterior Ischemic Optic Neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group
      receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP
      therapy besides standard medical treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ophthalmic artery blood flow velocity</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Central retinal artery flow velocity</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anterior Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Enhanced External conterpulsation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enhanced external counterpulsation</intervention_name>
    <description>EECP is performed for 1 hours every day, for a total of 36 hours.</description>
    <arm_group_label>Enhanced External conterpulsation</arm_group_label>
    <other_name>EECP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Standard drug therapy</description>
    <arm_group_label>Enhanced External conterpulsation</arm_group_label>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ischemic optic neuropathy

          -  within 1 month

        Exclusion Criteria:

          -  Hemorrhagic disease

          -  thrombophlebitis or infection lesions

          -  severe hypertensive patients

          -  Atrial fibrillation

          -  Aortic regurgitation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Zhang, Professor</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Zhang, MD</last_name>
    <phone>862087755766</phone>
    <phone_ext>8141</phone_ext>
    <email>Zhyan3@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat- sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang, MA</last_name>
      <phone>862087755766</phone>
      <phone_ext>8035</phone_ext>
      <email>Zhanglingaben@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Werner D, Michalk F, Harazny J, Hugo C, Daniel WG, Michelson G. Accelerated reperfusion of poorly perfused retinal areas in central retinal artery occlusion and branch retinal artery occlusion after a short treatment with enhanced external counterpulsation. Retina. 2004 Aug;24(4):541-7.</citation>
    <PMID>15300074</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 18, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>WenHui Zhu</investigator_full_name>
    <investigator_title>Oculist-in-charge</investigator_title>
  </responsible_party>
  <keyword>visual acuity</keyword>
  <keyword>artery flow velocity</keyword>
  <keyword>Enhanced External Counterpulsation</keyword>
  <keyword>Ischemic</keyword>
  <keyword>Optic Neuropathy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
